“…Fortunately, synthetic ghrelin analogs offer prolonged stability, significant plasma release for up to 24 h, oral bioavailability and the ability to co-bind CD36, which may be useful to diminish Aβ-driven microglial inflammation (Bulgarelli et al, 2009;Muller et al, 2015;Berlanga-Acosta et al, 2017). To further enhance efficacy, the combination of ghrelin agonists with other growth factors, such as EGF (Barco et al, 2011, del Barco et al, 2011 Barco-Herrera et al, 2013;Subiros et al, 2016), GH (Wu et al, 2009b;Zhou et al, 2017), insulin (Granado et al, 2011) and GLP-1 (Duarte et al, 2018), or DAG, to prevent AGencouraged glucose intolerance and hypoinsulinemia (Gauna et al, 2004;Kiewiet et al, 2009), may be profitable. On the other hand, due to the possible development of ghrelin resistance in AD and reports of gastrointestinal complications in some PD patients, clinical studies are warranted to monitor the longterm effectiveness of AG.…”